References
Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–26. https://doi.org/10.1056/NEJMoa041588
Sparano J, Gray R, Makower D, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379:111–21. https://doi.org/10.1056/NEJMoa1804710
Shaaban AM, Ball GR, Brannan RA, et al. A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences. Breast Cancer Res Treat. 2012;133:949–58. https://doi.org/10.1007/s10549-011-1856-9.
Williams AD, McGreevy CM, Tchou JC, De La Cruz LM. Utility of Oncotype DX in male breast cancer patients and impact on chemotherapy administration: a comparative study with female patients. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08473-y.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Williams, A.D., De La Cruz, L.M. ASO Author Reflections: No Profiling in Male Breast Cancer: Where We are and Where We Should Be. Ann Surg Oncol 27, 3612–3613 (2020). https://doi.org/10.1245/s10434-020-08504-8
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-020-08504-8